Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis.
about
Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes.FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?Implementation of quantitative and systems pharmacology in large pharma.Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis.Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model.Systems approaches in risk assessment.CPT: Pharmacometrics & Systems Pharmacology Publishes Its 100th Article.Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology.Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan?How Well Are We Applying Quantitative Methods to Reverse Translation to Inform Early Clinical Development?
P2860
Q30382924-195C6995-F719-4A6D-9731-BBFDFE4B783BQ34530510-3210421D-896C-4127-ABA1-291A718FEE92Q35179547-A907BCA2-5FA3-4876-BBB2-779A5CC1FC58Q35382875-FB10C34B-6E5A-4799-A9A3-D4A0752E8F35Q35760137-491A1BC6-D8EB-46B2-B398-F2064F6F7C93Q35801353-F92FBC10-497F-49DE-95B8-362BE01C5BF3Q36693715-5E6F819A-7AE5-4DF1-8528-FB6A5D87C549Q38093360-24C4729B-4598-4203-98BA-DDE007D47F0BQ40093478-CA8C1B3A-E3F1-47D3-BB51-9A183689E8B2Q40186234-AA61A1FE-A86B-4339-975B-31EE052169EDQ41582110-9CEC58D3-F827-48C3-A048-A1EA98E2CEC7Q46411883-89F63B77-7A11-4009-ACE7-680AB837BF47Q47255442-AAD29434-7E79-4E42-8082-0A2816622A65
P2860
Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Integrated pharmacometrics and ...... r management of endometriosis.
@ast
Integrated pharmacometrics and ...... r management of endometriosis.
@en
Integrated pharmacometrics and ...... r management of endometriosis.
@nl
type
label
Integrated pharmacometrics and ...... r management of endometriosis.
@ast
Integrated pharmacometrics and ...... r management of endometriosis.
@en
Integrated pharmacometrics and ...... r management of endometriosis.
@nl
prefLabel
Integrated pharmacometrics and ...... r management of endometriosis.
@ast
Integrated pharmacometrics and ...... r management of endometriosis.
@en
Integrated pharmacometrics and ...... r management of endometriosis.
@nl
P2093
P2860
P356
P1476
Integrated pharmacometrics and ...... r management of endometriosis.
@en
P2093
M Bennetts
P H van der Graaf
S W Martin
P2860
P356
10.1038/PSP.2012.10
P577
2012-10-17T00:00:00Z